Extends federal funding for the C.W. Bill Young cell transplantation program at $33,009,000 a year for fiscal years 2027 through 2031 and changes how the government manages its public cord blood inventory.

Official title: Stem Cell Therapeutic and Research Reauthorization Act of 2026

Next stop Senate floor: awaiting a vote

Timeline each lane is a chamber; dates pull from congress.gov actions

Senate

Introduced 17-MAR-2026

Approved by committee 17-JUN-2026

Reported 22-JUN-2026

On the calendar 22-JUN-2026

Key points

Authorizes $33,009,000 for each of fiscal years 2027 through 2031 for the C.W. Bill Young cell transplantation program.
Replaces the fixed goal of 150,000 new cord blood units with a supply level the Secretary of Health and Human Services sets.
Lets the Secretary move cord blood units from a bank that closes or fails clinical and quality standards to another qualified bank or approved entity.
Adds cord blood units and other emergent technologies to the periodic state-of-science review and sets its deadline three years after enactment.

AI-generated from the Reported to Senate text of 22-JUN-2026 · verify · report an error

Official CRS summary

Current. The Congressional Research Service's summary covers the bill's latest wording (Reported to Senate, 22-JUN-2026).

CRS is the Library of Congress's nonpartisan research office. Read it on congress.gov

Committee referrals (1)

Policy area

Health

Sponsor Jack Reed (D-RI) Cosponsors · 3

■ 2 R■ 1 D

2 Republicans

1 Democrat